159 related articles for article (PubMed ID: 22534869)
1. PhRMA survey of pharmacogenomic and pharmacodynamic evaluations: what next?
Grecco N; Cohen N; Warner AW; Lopez-Correa C; Truter SL; Snapir A; Piccoli SP; Wang D; Westelinck A; Hinman L; Franc MA;
Clin Pharmacol Ther; 2012 Jun; 91(6):1035-43. PubMed ID: 22534869
[TBL] [Abstract][Full Text] [Related]
2. Current practices for DNA sample collection and storage in the pharmaceutical industry, and potential areas for harmonization: perspective of the I-PWG.
Franc MA; Warner AW; Cohen N; Shaw PM; Groenen P; Snapir A
Clin Pharmacol Ther; 2011 Apr; 89(4):546-53. PubMed ID: 21368755
[TBL] [Abstract][Full Text] [Related]
3. Coding of DNA samples and data in the pharmaceutical industry: current practices and future directions--perspective of the I-PWG.
Franc MA; Cohen N; Warner AW; Shaw PM; Groenen P; Snapir A;
Clin Pharmacol Ther; 2011 Apr; 89(4):537-45. PubMed ID: 21346752
[TBL] [Abstract][Full Text] [Related]
4. The impact of FDA guidance on pharmacogenomic data submissions on drug development.
Little S
IDrugs; 2005 Aug; 8(8):648-50. PubMed ID: 16044373
[TBL] [Abstract][Full Text] [Related]
5. An industry survey on current practices in the design and analysis of active control studies.
Chuang-Stein C; Sanders C; Snapinn S
J Biopharm Stat; 2004 May; 14(2):349-58. PubMed ID: 15206532
[TBL] [Abstract][Full Text] [Related]
6. The drug diagnostic co-development concept paper: commentary from the 3rd FDA-DIA-PWG-PhRMA-BIO Pharmacogenomics Workshop.
Hinman LM; Huang SM; Hackett J; Koch WH; Love PY; Pennello G; Torres-Cabassa A; Webster C
Pharmacogenomics J; 2006; 6(6):375-80. PubMed ID: 16652120
[TBL] [Abstract][Full Text] [Related]
7. Challenges in obtaining adequate genetic sample sets in clinical trials: the perspective of the industry pharmacogenomics working group.
Warner AW; Bhathena A; Gilardi S; Mohr D; Leong D; Bienfait KL; Sarang J; Duprey S; Franc MA; Nelsen A; Snapir A
Clin Pharmacol Ther; 2011 Apr; 89(4):529-36. PubMed ID: 21346757
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop.
Lesko LJ; Salerno RA; Spear BB; Anderson DC; Anderson T; Brazell C; Collins J; Dorner A; Essayan D; Gomez-Mancilla B; Hackett J; Huang SM; Ide S; Killinger J; Leighton J; Mansfield E; Meyer R; Ryan SG; Schmith V; Shaw P; Sistare F; Watson M; Worobec A
J Clin Pharmacol; 2003 Apr; 43(4):342-58. PubMed ID: 12723455
[TBL] [Abstract][Full Text] [Related]
9. Implications of pharmacogenomics for drug development.
Kirk RJ; Hung JL; Horner SR; Perez JT
Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
[TBL] [Abstract][Full Text] [Related]
10. Regulatory agency consideration of pharmacogenomics.
Pendergast MK
Exp Biol Med (Maywood); 2008 Dec; 233(12):1498-503. PubMed ID: 18849547
[TBL] [Abstract][Full Text] [Related]
11. Current pharmacogenomic approaches to clinical drug development.
Murphy MP
Pharmacogenomics; 2000 May; 1(2):115-23. PubMed ID: 11256585
[TBL] [Abstract][Full Text] [Related]
12. Ethics and policy perspectives on personalized medicine in the post-genomic era.
Landon MR
J Biolaw Bus; 2005; 8(3):28-36. PubMed ID: 16459425
[TBL] [Abstract][Full Text] [Related]
13. Innovative approaches for designing and analyzing adaptive dose-ranging trials.
Bornkamp B; Bretz F; Dmitrienko A; Enas G; Gaydos B; Hsu CH; König F; Krams M; Liu Q; Neuenschwander B; Parke T; Pinheiro J; Roy A; Sax R; Shen F
J Biopharm Stat; 2007; 17(6):965-95. PubMed ID: 18027208
[TBL] [Abstract][Full Text] [Related]
14. Report raises questions about drug companies advertising budgets.
AIDS Policy Law; 1999 Aug; 14(14):1, 6. PubMed ID: 11366996
[TBL] [Abstract][Full Text] [Related]
15. PhRMA white paper on ADME pharmacogenomics.
Williams JA; Andersson T; Andersson TB; Blanchard R; Behm MO; Cohen N; Edeki T; Franc M; Hillgren KM; Johnson KJ; Katz DA; Milton MN; Murray BP; Polli JW; Ricci D; Shipley LA; Vangala S; Wrighton SA
J Clin Pharmacol; 2008 Jul; 48(7):849-89. PubMed ID: 18524998
[TBL] [Abstract][Full Text] [Related]
16. Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop.
Salerno RA; Lesko LJ
Pharmacogenomics J; 2006; 6(2):78-81. PubMed ID: 16402087
[No Abstract] [Full Text] [Related]
17. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective.
Chu V; Einolf HJ; Evers R; Kumar G; Moore D; Ripp S; Silva J; Sinha V; Sinz M; Skerjanec A
Drug Metab Dispos; 2009 Jul; 37(7):1339-54. PubMed ID: 19389860
[TBL] [Abstract][Full Text] [Related]
19. Company profile: PGXIS Ltd.
McCarthy A
Pharmacogenomics; 2011 Sep; 12(9):1253-6. PubMed ID: 21919604
[TBL] [Abstract][Full Text] [Related]
20. Global requirements for DNA sample collections: results of a survey of 204 ethics committees in 40 countries.
Ricci DS; Broderick ED; Tchelet A; Hong F; Mayevsky S; Mohr DM; Schaffer ME; Warner AW; Hakkulinen P; Snapir A
Clin Pharmacol Ther; 2011 Apr; 89(4):554-61. PubMed ID: 21346753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
